Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cidara Therapeutics, Inc.CDTX · Entity 69639 | 10% owner | November 15, 2017 | November 16, 2017 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | 10% owner | May 24, 2021 | May 26, 2021 |
| MACROGENICS INCMGNX · Entity 6104 | 10% owner | October 02, 2023 | October 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cidara Therapeutics, Inc.
Report date November 15, 2017 · Filed November 16, 2017
Jointly reported with BB BIOTECH AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,295,272 |
Reported balance
After 2017-11-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-11-15 · Purchase · Acquired 60,000 · Balance 2,295,272 |
Esperion Therapeutics, Inc.
Report date May 24, 2021 · Filed May 26, 2021
Jointly reported with BB BIOTECH AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,477,964 |
Reported balance
After 2021-05-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-24 · Purchase · Acquired 100,000 · Balance 4,477,964 |
MACROGENICS INC
Report date October 02, 2023 · Filed October 04, 2023
Jointly reported with BB BIOTECH AG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,929,963 |
Reported balance
After 2023-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-02 · Purchase · Acquired 150,000 · Balance 9,929,963 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Molecular Templates, Inc.
Report date November 14, 2024 · Filed November 19, 2024
Jointly reported with BB BIOTECH AG
Section 16 reporting ended · disclosed 2024-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-14 · Sale · Disposed 1,279,820 · Balance 0 |
| Prefunded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 134,667 |
Reported balance
After 2024-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-02 · Purchase · Acquired 134,667 · Balance 134,667 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. |
| Common Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2029-04-02 | Direct | 769,334 |
Reported balance
After 2024-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-02 · Purchase · Acquired 769,334 · Balance 769,334 F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.
Radius Health, Inc.
Report date August 15, 2022 · Filed August 30, 2022
Jointly reported with BB BIOTECH AG
Section 16 reporting ended · disclosed 2022-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-11 · Other · Disposed 8,733,538 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of June 23, 2022, by and among the Issuer, Ginger Acquisition, Inc. ("Parent") and Ginger Merger Sub, Inc. ("Purchaser"), the Issuer merged with and into Purchaser on August 15, 2022, following a tender offer by Purchaser (the "Offer") to purchase each outstanding share of the Issuer's common stock in exchange for (i) $10.00, in cash, without interest and less applicable tax withholdings, plus (ii) one contractual contingent value right, which represents the right to receive a contingent payment of $1.00 (without interest thereon) upon the satisfaction of certain conditions (collectively, the "Offer Price"). Pursuant to the Merger Agreement and the Offer, the Purchaser acquired all of the shares of the Company held by the Reporting Persons and merged with and into the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2021 Filed Apr 9, 2021 17:52 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 300,000 | $8.22 | $2,466,660.00 |
DisclosureSEC source: 0000899243-21-015470 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,816,105 Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 17:52 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 200,000 | $8.24 | $1,648,160.00 |
DisclosureSEC source: 0000899243-21-015470 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,516,105 Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 17:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 200,000 | $9.44 | $1,887,100.00 |
DisclosureSEC source: 0000899243-21-015196 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,316,105 Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 17:44 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $11.45 | $915,848.00 |
DisclosureSEC source: 0000899243-21-014121 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,116,105 Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 19:46 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 75,000 | $11.48 | $860,835.00 |
DisclosureSEC source: 0000899243-21-008183 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,036,105 Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 19:46 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 235,004 | $11.29 | $2,653,030.66 |
DisclosureSEC source: 0000899243-21-008183 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,961,105 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 22:28 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 1,185,770 | $12.65 | $14,999,990.50 |
DisclosureSEC source: 0000899243-21-007418 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,726,101 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 18:33 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $11.69 | $935,344.00 |
DisclosureSEC source: 0000899243-21-004636 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,540,331 Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 21:58 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $11.94 | $955,000.00 |
DisclosureSEC source: 0000899243-21-003875 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,460,331 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 17:36 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 170,000 | $8.18 | $1,391,416.00 |
DisclosureSEC source: 0000899243-20-033533 · doc4.xml · nonDerivative · entry 3 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380,331 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 17:36 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 150,000 | $8.39 | $1,258,425.00 |
DisclosureSEC source: 0000899243-20-033533 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210,331 Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 17:36 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 125,000 | $8.62 | $1,077,600.00 |
DisclosureSEC source: 0000899243-20-033533 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,060,331 Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 11:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $9.16 | $732,472.00 |
DisclosureSEC source: 0000899243-20-030775 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,935,331 Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 11:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $9.05 | $724,144.00 |
DisclosureSEC source: 0000899243-20-030775 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,855,331 Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 21:09 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 470,335 | $8.33 | $3,919,960.02 |
DisclosureSEC source: 0000899243-20-030625 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,775,331 Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:09 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 75,000 | $10.86 | $814,230.00 |
DisclosureSEC source: 0000899243-20-030625 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,304,996 Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 16:29 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 100,000 | $14.26 | $1,426,230.00 |
DisclosureSEC source: 0000899243-20-030614 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,455,714 Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 21:37 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 200,000 | $25.31 | $5,062,120.00 |
DisclosureSEC source: 0000899243-20-030389 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,947,964 Read SEC document |
| October 30, 2020 Filed Nov 4, 2020 20:05 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $8.83 | $706,312.00 |
DisclosureSEC source: 0000899243-20-030364 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,229,996 Read SEC document |
| October 28, 2020 Filed Nov 4, 2020 20:05 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 80,000 | $9.40 | $751,688.00 |
DisclosureSEC source: 0000899243-20-030364 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,149,996 Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 16:01 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 200,000 | $11.69 | $2,338,680.00 |
DisclosureSEC source: 0000899243-20-025283 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,355,714 Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 20:03 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 199,029 | $11.33 | $2,255,117.99 |
DisclosureSEC source: 0000899243-20-024980 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,155,714 Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 18:40 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 25,000 | $13.21 | $330,177.50 |
DisclosureSEC source: 0000899243-20-018807 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,956,685 Read SEC document |
| April 30, 2020 Filed May 4, 2020 21:32 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 50,000 | $15.75 | $787,555.00 |
DisclosureSEC source: 0000899243-20-011906 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,931,685 F1 · balance_after: Includes 6,881,685 shares of common stock previously held by Biotech Growth N.V. Biotech Growth N.V. and Biotech Target N.V. are both wholly-owned subsidiaries of BB Biotech AG. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 17:51 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 20,000 | $52.12 | $1,042,398.00 |
DisclosureSEC source: 0000899243-20-002016 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,747,964 Read SEC document |
| November 06, 2019 Filed Nov 8, 2019 19:54 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 75,000 | $37.30 | $2,797,560.00 |
DisclosureSEC source: 0000899243-19-026965 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,727,964 Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 20:09 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 80,000 | $33.78 | $2,702,208.00 |
DisclosureSEC source: 0000899243-19-022997 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,652,964 Read SEC document |
| July 23, 2019 Filed Jul 25, 2019 16:42 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $42.65 | $2,132,565.00 |
DisclosureSEC source: 0000899243-19-020344 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,572,964 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 23:50 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $49.89 | $2,494,355.00 |
DisclosureSEC source: 0000899243-19-008014 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,522,964 Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 22:10 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 80,000 | $41.29 | $3,303,256.00 |
DisclosureSEC source: 0000899243-19-000685 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,472,964 Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 16:44 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $39.91 | $1,995,725.00 |
DisclosureSEC source: 0000899243-18-031655 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,392,964 Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 18:14 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 60,000 | $47.73 | $2,864,070.00 |
DisclosureSEC source: 0000899243-18-031388 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,342,964 Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:23 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $46.14 | $2,306,970.00 |
DisclosureSEC source: 0000899243-18-021471 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,282,964 Read SEC document |
| July 12, 2018 Filed Jul 13, 2018 15:45 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $41.77 | $2,088,300.00 |
DisclosureSEC source: 0000899243-18-019836 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,232,964 Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 15:55 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $39.48 | $1,973,805.00 |
DisclosureSEC source: 0000899243-18-019108 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,182,964 Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:43 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 60,000 | $38.57 | $2,314,224.00 |
DisclosureSEC source: 0000899243-18-017843 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,132,964 Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 18:59 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 60,000 | $37.79 | $2,267,292.00 |
DisclosureSEC source: 0000899243-18-015926 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072,964 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 18:34 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 60,000 | $38.47 | $2,308,440.00 |
DisclosureSEC source: 0000899243-18-015413 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012,964 Read SEC document |
| May 21, 2018 Filed May 22, 2018 19:49 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 80,000 | $38.77 | $3,101,760.00 |
DisclosureSEC source: 0000899243-18-013665 · doc4.xml · nonDerivative · entry 2 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,952,964 Read SEC document |
| May 18, 2018 Filed May 22, 2018 19:49 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 50,000 | $42.24 | $2,112,010.00 |
DisclosureSEC source: 0000899243-18-013665 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,872,964 Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 17:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | PurchaseCommon Stock | 60,000 | $7.57 | $453,966.00 |
DisclosureSEC source: 0000899243-17-026540 · doc4.xml · nonDerivative · entry 1 BIOTECH TARGET N V · CIK 0001259870 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,295,272 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.